Our firm encourages a collaborative environment that promotes the team over the Individual. We act in the best interest of patients, employees, investors and portfolio companies. We base our decisions on improving healthcare outcomes for patients by investing in differentiated medical innovations. The medical technologies that we invest in are supported by human clinical trials. These principals ensure that shareholder value is maximized within each investment.
Inspiros’ Principals combined 30 years of experience in medical technology provides us with an edge in selecting, evaluating and investing in medical technologies. The medtech industry is growing, has profitable margins and favorable investment characteristics. We focus exclusively on differentiated, early growth stage medtech companies. We believe the technologies that will generate the greatest investment returns are the ones supported by human clinical data that focus on patient outcomes and value based care. The clinical data is generated by trials conducted on human volunteers with the goal of providing the information needed to support the efficacy of the device or diagnostic and result in the final regulatory approval.